Research
The Next Wave of Life Sciences M&A
Navigating policy, power, and progress
December 04, 2025
The next wave of life sciences M&A demands precision.
Life sciences dealmaking is back on the offense. Breakthroughs in biotechnology, metabolic health, and AI have restored momentum—and sharpened expectations.
But higher velocity comes with higher scrutiny. Policy shifts, pricing pressure, and rising digital maturity standards are rewriting how value is created, measured, and protected. Success now depends on execution, not optimism.
Download West Monroe’s Research Report to:
• Understand where deal volume is rising—and why execution now sets the pace
• See how policy shifts are reshaping valuation, diligence, and portfolio moves
• Learn why AI maturity now predicts who captures post-close value
